Research conducted by Alberto Ascherio, professor of epidemiology and nutrition at the Harvard School of Public Health (USA), indicates that vitamin D could slow the progression of the disease in people with multiple sclerosis, as well as reduce harmful brain activity. Multiple sclerosis is a disease of the central nervous system, and vitamin D levels may be associated with the disease process, according to a study published in the scientific journal JAMA Neurology. Hence, immunogenetic biomedicine can be used in its preventive aspect.
The researchers examined whether serum concentrations of 25-hydroxyvitamin D, a marker reflecting vitamin D status, are related to multiple sclerosis activity and progression in patients with a first episode of multiple sclerosis. Blood levels of 25-hydroxyvitamin D were assessed as part of a randomized trial originally designed to study patients treated with interferon beta-1b.
Scientists analyzed vitamin D levels in 465 participants with signs of multiple sclerosis who took part in a trial designed to test treatment with interferon beta-1b. These patients were followed for the next five years, undergoing magnetic resonance imaging so that researchers could explore disease-related brain damage.
During the first 12 months of follow-up, increases of 50 nmol/L in 25[OH]D were associated with a 57% lower risk of new active brain lesions.
Researchers also found a 57% lower chance of relapse, a 25% lower annual increase in T2 lesion size, and a 0.41% lower brain size from 12 to 60 months.
At Biosalud, we use immunogenetic biomedicine to treat diseases from their genetic origin. In this century, immunogenetic medicine plays an important role in health.
Immunogenetic medicine is one of the most important scientific advances of the 21st century, and Biosalud is a pioneer in its two main areas of application: preventive and therapeutic.
